GSK plc (GLAXF)
OTCMKTS · Delayed Price · Currency is USD
17.15
-0.91 (-5.04%)
Jul 18, 2025, 3:58 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
HIV | 7.09B | Log In | Log In | Log In | Log In | Upgrade |
HIV Growth | 9.12% | Log In | Log In | Log In | Log In | Upgrade |
Other | -30.77B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 5.89% | Log In | Log In | Log In | Log In | Upgrade |
Meningitis | 1.44B | Log In | Log In | Log In | Log In | Upgrade |
Meningitis Growth | 16.34% | Log In | Log In | Log In | Log In | Upgrade |
Influenza | 408.00M | Log In | Log In | Log In | Log In | Upgrade |
Influenza Growth | -21.58% | Log In | Log In | Log In | Log In | Upgrade |
Established Vaccines | 3.34B | Log In | Log In | Log In | Log In | Upgrade |
Established Vaccines Growth | 0.33% | Log In | Log In | Log In | Log In | Upgrade |
Shingles | 3.36B | Log In | Log In | Log In | Log In | Upgrade |
Shingles Growth | -7.64% | Log In | Log In | Log In | Log In | Upgrade |
Oncology | 1.41B | Log In | Log In | Log In | Log In | Upgrade |
Oncology Growth | 78.80% | Log In | Log In | Log In | Log In | Upgrade |
Respiratory, Immunology and Inflammation | 3.30B | Log In | Log In | Log In | Log In | Upgrade |
Respiratory, Immunology and Inflammation Growth | 13.37% | Log In | Log In | Log In | Log In | Upgrade |
Respiratory | 7.21B | Log In | Log In | Log In | Log In | Upgrade |
Respiratory Growth | 6.12% | Log In | Log In | Log In | Log In | Upgrade |
Other General Medicines | 3.22B | Log In | Log In | Log In | Log In | Upgrade |
Other General Medicines Growth | -5.20% | Log In | Log In | Log In | Log In | Upgrade |
Total Commerical Operations | 31.38B | Log In | Log In | Log In | Log In | Upgrade |
Total Commerical Operations Growth | 2.57% | Log In | Log In | Log In | Log In | Upgrade |
Total Consumer Healthcare | - | Log In | Log In | Log In | Log In | Upgrade |
Pandemic | - | Log In | Log In | Log In | Log In | Upgrade |
Pandemic Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Pandemic Vaccines | - | Log In | Log In | Log In | Log In | Upgrade |
Pandemic Vaccines Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | -30.77B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 5.89% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | -3.31B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 349.32% | Log In | Log In | Log In | Log In | Upgrade |
Commercial Operations Segment Profit | 15.34B | Log In | Log In | Log In | Log In | Upgrade |
Commercial Operations Segment Profit Growth | 1.74% | Log In | Log In | Log In | Log In | Upgrade |
Research & Development Segment Profit | -5.85B | Log In | Log In | Log In | Log In | Upgrade |
Research & Development Segment Profit Growth | 3.64% | Log In | Log In | Log In | Log In | Upgrade |
Consumer Healthcare Segment Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Other | -3.31B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 349.32% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
US Revenue | 16.38B | Log In | Log In | Log In | Log In | Upgrade |
US Revenue Growth | 2.53% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 6.67B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | 4.83% | Log In | Log In | Log In | Log In | Upgrade |
International | 8.33B | Log In | Log In | Log In | Log In | Upgrade |
International Growth | 0.84% | Log In | Log In | Log In | Log In | Upgrade |